Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Chronic Obstructive Pulmonary Disorder (COPD): Update Bulletin [Feb 2016]

Product Code:
Publication Date:
February 2016

Gain new KOL insights on the latest events that have the potential to shape the oncology biosimilars market. Topics covered include opinions about data from Sandoz’s PROTECT 1 and PROTECT 2 studies which both compared the safety and efficacy of LA-EP2006 (a proposed pegfilgrastim biosimilar) to Amgen’s Neulasta in patients with breast cancer; the regulatory filing of Celltrion’s proposed rituximab biosimilar, CT-P10, to the European Medicines Agency (EMA), and the concerns KOLs have in relation to the potential for indication extrapolation from the rheumatology to oncology settings; the potential impact of The Centers for Medicare & Medicaid Services’s (CMS) final rule on how it plans to reimburse for biosimilars covered under Medicare Part B in the US.

Key Questions Answered in this Update Bulletin:

  • What is the role of MABAs (muscarinic antagonists/beta2 agonists) and what advantages do they offer over current bronchodilators?
  • What is the rationale for developing MABA/ICS combinations? 
  • Will MABA/ICS provide similar benefits to the more clinically advanced LAMA/LABA/ICS combinations? 
  • Could a MABA be combined with an ICS and an additional anti-inflammatory agent? 
  • Will asthma COPD overlap syndrome (ACOS) be recognized by physicians or regulators as a distinct clinical entity?
  • Could Novartis’s novel ‘Smart’ Breezhaler/Neohaler device improve adherence?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved